MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma
Hyuk Moon,Simon Weonsang Ro +1 more
TLDR
The MAPK/ERK signaling pathway is activated in more than 50% of human HCC cases; however, activating mutations in RAS and RAF genes are rarely found in HCC as mentioned in this paper.Abstract:
Hepatocellular carcinoma (HCC) is a major health concern worldwide, and its incidence is increasing steadily. Recently, the MAPK/ERK signaling pathway in HCC has gained renewed attention from basic and clinical researchers. The MAPK/ERK signaling pathway is activated in more than 50% of human HCC cases; however, activating mutations in RAS and RAF genes are rarely found in HCC, which are major genetic events leading to the activation of the MAPK/ERK signaling pathway in other cancers. This suggests that there is an alternative mechanism behind the activation of the signaling pathway in HCC. Here, we will review recent advances in understanding the cellular and molecular mechanisms involved in the activation of the MAPK/ERK signaling pathway and discuss potential therapeutic strategies targeting the signaling pathway in the context of HCC.read more
Citations
More filters
Journal ArticleDOI
Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma.
Eun Jin Sun,Miriam Wankell,Pranavan Palamuthusingam,Craig McFarlane,Lionel Hebbard,Lionel Hebbard +5 more
TL;DR: The role of the PI3K/Akt/mTOR pathway in the pathogenesis of hepatocellular carcinoma (HCC) was investigated in this paper, focusing on its downstream effectors such as glycogen synthase kinase-3 (GSK-3), cAMP-response element-binding protein (CREB), forkhead box O protein (FOXO), murine double minute 2 (MDM2), p53, and nuclear factor-κB (NF)-κB), and the cellular processes of lipogenesis and autophagy.
Journal ArticleDOI
Drug Resistance and Endoplasmic Reticulum Stress in Hepatocellular Carcinoma
TL;DR: Interestingly, the three different arms of the ER stress signaling pathways have been shown to drive chemoresistance in several tumors and could therefore form a promising therapeutic target.
Journal ArticleDOI
Exosome-based nanomedicine for cancer treatment by targeting inflammatory pathways: Current status and future perspectives.
Mohammad Azam Ansari,Muthu Thiruvengadam,Baskar Venkidasamy,Mohammad N. Alomary,Abdulmohsin J. Alamoudi,Ill-Min Chung,Mohammad Sharifi,Maksim Rebezov +7 more
TL;DR: Exosome-mimetic vesicles are receiving much interest for developing nano-sized delivery systems and their potential therapeutic roles in cancer therapy has been thoroughly discussed in this article , where the most commonly dysregulated inflammatory pathways linked to cancer include NF-κB, MAPK, JAK-STAT, and PI3K/AKT.
Journal ArticleDOI
Investigations of nitazoxanide molecular targets and pathways for the treatment of hepatocellular carcinoma using network pharmacology and molecular docking
TL;DR: Theoretical basis for the notion that nitazoxanide may have distinct therapeutic effects in HCC is offered, and the identified pharmacological targets and pathways might function as biomarkers for HCC therapy are identified.
Journal ArticleDOI
The Pyroptosis-Related Gene Signature Predicts the Prognosis of Hepatocellular Carcinoma
TL;DR: The novel pyroptosis-related genes signature can predict the prognosis of patients with HCC and insight into new cell death targeted therapies.
References
More filters
Journal ArticleDOI
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn,Shukui Qin,Masafumi Ikeda,Peter R. Galle,Michel Ducreux,Tae-You Kim,Masatoshi Kudo,Valeriy Breder,Philippe Merle,Ahmed O Kaseb,Daneng Li,Wendy Verret,Derek-Zhen Xu,Sairy Hernandez,Juan Liu,Chen Huang,Sohail M. Mulla,Yulei Wang,Ho Yeong Lim,Andrew X. Zhu,Ann-Lii Cheng,IMbrave Investigators +21 more
TL;DR: In patients with unresectable hepatocellular carcinoma, atezolIZumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib.
Journal ArticleDOI
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix,Shukui Qin,Philippe Merle,Alessandro Granito,Yi Hsiang Huang,György Bodoky,Marc Pracht,Osamu Yokosuka,Olivier Rosmorduc,Valeriy Breder,René Gerolami,Gianluca Masi,Paul Ross,Tianqiang Song,Jean-Pierre Bronowicki,Isabelle Ollivier-Hourmand,Masatoshi Kudo,Ann-Lii Cheng,Josep M. Llovet,Josep M. Llovet,Josep M. Llovet,Richard S. Finn,Marie Aude Leberre,Annette Baumhauer,Gerold Meinhardt,Guohong Han +25 more
TL;DR: Regorafenib is the only systemic treatment shown to provide survival benefit in HCC patients progressing on sorafenIB treatment, and future trials should explore combinations of regorAFenib with other systemic agents and third-line treatments for patients who fail or who do not tolerate the sequence of sorafanib and regorafinib.
Hepatocellular carcinoma.
Josep M. Llovet,Robin Kate Kelley,Augusto Villanueva,Amit G. Singal,Eli Pikarsky,Sasan Roayaie,Riccardo Lencioni,Kazuhiko Koike,Jessica Zucman-Rossi,Richard S. Finn +9 more
TL;DR: In this paper, the authors used non-invasive criteria to diagnose hepatocellular carcinoma (HCC) and showed that 25% of all HCCs present potentially actionable mutations, which are yet to translate into clinical practice.
Journal ArticleDOI
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets
Kornelius Schulze,Sandrine Imbeaud,Eric Letouzé,Ludmil B. Alexandrov,Ludmil B. Alexandrov,Julien Calderaro,Sandra Rebouissou,Gabrielle Couchy,Clément Meiller,Jayendra Shinde,Frédéric Soysouvanh,Anna Line Calatayud,Roser Pinyol,Laura Pelletier,Charles Balabaud,Alexis Laurent,Jean-Frédéric Blanc,Vincenzo Mazzaferro,Fabien Calvo,Augusto Villanueva,Jean-Charles Nault,Paulette Bioulac-Sage,Michael R. Stratton,Josep M. Llovet,Josep M. Llovet,Jessica Zucman-Rossi +25 more
TL;DR: Exome sequencing analysis of 243 liver tumors identified mutational signatures associated with specific risk factors, mainly combined alcohol and tobacco consumption and exposure to aflatoxin B1, and defined the extensive landscape of altered genes and pathways in HCC.
Journal ArticleDOI
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon,Karen Rex,Anne Y. Saiki,Christopher Mohr,Keegan Cooke,Dhanashri Bagal,Kevin Gaida,Tyler Holt,Charles G. Knutson,Neelima Koppada,Brian A. Lanman,Jonathan Werner,Aaron S. Rapaport,Tisha San Miguel,Roberto Ortiz,Roberto Ortiz,Tao Osgood,Ji Rong Sun,Xiaochun Zhu,Xiaochun Zhu,John D. McCarter,Laurie P. Volak,Laurie P. Volak,Brett E. Houk,Marwan Fakih,Bert H. O'Neil,Timothy J. Price,Gerald Steven Falchook,Jayesh Desai,James Kuo,Ramaswamy Govindan,David S. Hong,Wenjun Ouyang,H. Henary,Tara Arvedson,Victor J. Cee,J. Russell Lipford +36 more
TL;DR: Treatment of KRASG 12C-mutant cancer cells with the KRAS(G12C) inhibitor AMG 510 leads to durable response in mice, and anti-tumour activity in patients suggests that AMG510 could be effective in patients for whom treatments are currently lacking.
Related Papers (5)
Mitogen-activated protein kinases in hepatocellular carcinoma development
Lihua Min,Baokun He,Lijian Hui +2 more
Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma.
Manali Dimri,Ande Satyanarayana +1 more